Although it is not extensively studied in breast cancer, the overexpression of CRLF2, present in Xp22.33, has been demonstrated to be a marker of poor outcome of pediatric and adult B-precursor acute lymphoblastic leucemia (ALL) (as reviewed in [39]). Here, CRLF2 is linked to breast cancer.